Staging Non-Hodgkin Lymphoma [PDF]
CA: A Cancer Journal for Clinicians, 2005 Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification.
openaire +4 more sources
The Non-Hodgkin's Lymphomas [PDF]
CA: A Cancer Journal for Clinicians, 1985 J E, Ultmann, R H, Jacobs
openaire +4 more sources
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Primary Non-Hodgkin Lymphoma of The Cervix [PDF]
International Journal of Hematology-Oncology and Stem Cell Research, 2011 Background: There are only a few reports that exist regarding primary non-Hodgkin lymphoma of the genital tract. In this article, one case of primary B-cell type non-Hodgkin lymphoma (NHL) of the cervix is presented.
Haleh Ayatollahi +2 more
doaj +2 more sources
Human leukocyte antigens and genetic susceptibility to lymphoma [PDF]
, 2015 Familial aggregation, coupled with ethnic variation in incidence, suggests that inherited susceptibility plays a role in the development of lymphoma, and the search for genetic risk factors has highlighted the contribution of the human leukocyte antigen (
Jarrett, R.F., McAulay, K.A.
core +1 more source
Lymphohaematopoietic malignancies in Scottish military veterans: Retrospective cohort study of 57,000 veterans and 173,000 non-veterans [PDF]
, 2017 Background: Lymphohaematopoietic malignancies are common in the general population. There have been concerns that military service may be associated with increased risk as a result of occupational exposures.
Bergman, Beverly P. +2 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Association of group erythrocyte antigens and B-cell non-Hodgkin lymphoma
Regulatory Mechanisms in Biosystems, 2016 We analyzed the frequency distribution of blood groups AB0, Rhesus and Kell in patients with B-cell non-Hodgkin lymphoma. An increase of D− patients (31.0%) among ill in comparison to healthy individuals (16.5%) was found.
U. V. Tymoshenko +4 more
doaj +1 more source
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]
, 2016 Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni +7 more
core +1 more source
BMJ, 2018 The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna +3 more
openaire +3 more sources